GW Pharmaceuticals’ Epidiolex drug reduces children’s seizures in phase III trial
The 120-patient trial demonstrated that patients taking Epidiolex achieved a median reduction in monthly convulsive seizures of 39%, compared with a 13% reduction for those on a placebo,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.